Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab
Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab in Second-line Treatment of Advanced Gastric Cancer: a Prospective, Single Arm Clinical Study
Gastric Cancer
DRUG: Disitamab Vedotin combined with Sintilimab
ORR, Objective response rate, 1 year
PFS, Progression-free survival, 2 years|OS, Overall Survival, 2 years
We initiated the efficacy and safety of the first Disitamab Vedotin combined with Sintilimab in second-line therapy in patients with advanced gastric cancer with positive HER2 or low expression of HER2.